A medical-device change requires biocompatibility reassessment when it could alter biological hazards, patient exposure, the final finished device, or the applicability of existing evidence.
Reassessment is a documented decision process, not an automatic instruction to repeat every test. The output should identify what remains applicable, what needs stronger justification, and whether targeted chemistry, toxicology, literature, or testing is actually needed.
This page is the educational trigger guide. Use it to recognize when a change should reopen the biological evaluation. For a documented decision on one defined change, use the material change assessment service; for internal screening, begin with the free change-control triage tool.
When Does a Material Change Require Biological Re-Evaluation?
Under the ISO 10993-1:2025 biological-safety framework, a change should be assessed when it can alter the hazards, exposures, final finished device, or evidence on which the current biological evaluation relies. The practical challenge is determining which assumptions have changed and documenting that decision within the wider ISO 14971 risk-management process.
Changes That Commonly Trigger Re-Evaluation
- Raw material supplier change: nominally identical specifications can still hide differences in impurities, processing aids, or residuals.
- Formulation or additive change: colorants, fillers, plasticizers, stabilizers, or resin blends can materially affect the biological risk story.
- Sterilization change: switching between EO, gamma, e-beam, steam, or other methods can alter residues and final-device chemistry.
- Manufacturing or process change: cleaning, coating, surface treatment, assembly, or packaging changes may affect what reaches the patient.
- Indication or contact-profile expansion: a geometry or use change can push the device into a different contact type or duration category.
The Right Way to Think About Reassessment
The key question is not just "Did something change?" It is "Does the existing evidence still represent the changed device?" If the answer is uncertain, the biological evaluation needs a structured review rather than a shortcut statement that nothing important changed.
The Structured Re-Evaluation Process
- Step 1: document the change clearly. Define the old state, the new state, and why the change occurred.
- Step 2: reassess contact and endpoint logic. Confirm whether contact type, duration, or applicable endpoints have shifted.
- Step 3: compare evidence against the changed device. Review testing, literature, equivalence arguments, and chemistry data for continued relevance.
- Step 4: identify gaps. Determine whether chemistry, toxicology, literature, or targeted testing needs to be updated.
- Step 5: update the file. Revise the BEP, BER, risk-management cross-references, and submission narrative where needed.
Why Supplier Changes Are Often Missed
Supplier changes are one of the most common hidden triggers because teams often rely on matching material names or high-level specifications. But supplier-specific impurities, processing differences, or undocumented minor chemistry differences can still matter. That is why "same spec" is not always the end of the discussion.
When Retesting Is Not Automatically Required
Reassessment does not always mean new biological testing. In many cases, strong comparability logic, updated chemistry, targeted toxicology, or a revised endpoint rationale can close the gap more efficiently than running a broad new test program. The key is to make that decision consciously and document it well.
If the changed device would make you uneasy using the old evidence package without explanation, that is usually a sign the file needs a structured re-evaluation rather than a one-line change-control conclusion.
What a Good Output Looks Like
A good reassessment ends with a clear answer: what changed, what endpoints or assumptions are affected, what existing evidence remains valid, what additional support is needed, and what exact BEP, BER, or risk-file updates should now be made.
Key References
- ISO 10993-1:2025 for biological-safety evaluation within risk management and lifecycle control.
- ISO 14971:2019 for assessing and controlling medical-device risk throughout the lifecycle.
- FDA guidance on deciding when to submit a new 510(k) for a device change, including risk-based documentation of modifications.
- Regulation (EU) 2017/745 for keeping risk management and technical documentation current and addressing changes to device design or characteristics.
Why this perspective is practical
Arvind Rathore is the founder of MedDev Advisory, where his work focuses on ISO 10993 biological-evaluation strategy and documentation. Before establishing the practice, he was a Marie Skłodowska-Curie Early Stage Researcher at INSERM U1026 Biotis within the ImplantSens network. His research covered implantable electrochemical biosensors, cytotoxicity, oxidative stress, sterilization effects and biomaterial–cell interactions, with research placements in France, Germany and Sweden. Peer-reviewed work in Bioelectrochemistry and Advanced Sensor Research also informs his evidence-led approach. Read more about Arvind Rathore.
Need to decide whether a device change requires updated chemistry, toxicology, testing, or just a tighter rationale?
Use the Biological Evaluation Strategy Handbook for the biological-safety lifecycle framework. The available Medical Device Change Control and Evidence Decisions handbook extends the reasoning across supplier, design, manufacturing, packaging, software and market-route questions. If one defined change needs a decision now, move to qualified assessment rather than treating this educational guide as the record.